Synapse Open Synapse
Biology

Pharmacologically targeting CDK12 induces BRCAness and synergizes with merestinib to exacerbate DNA damage in high-risk neuroblastoma

Cell Reports · · 72 min read

Goulding et al. pharmacologically target CDK12 in neuroblastoma cells to downregulate DNA damage repair gene expression, resulting in apoptosis. The multi-kinase inhibitor merestinib emerged as highly synergistic with CDK12 inactivation, exacerbating DNA damage.

Latest from Cell Reports